Mayo Clinic surgeons direct robotic 'hands' to perform surgery

September 05, 2002

ROCHESTER, MINN. -- For the first time, surgeons at Mayo Clinic in Rochester, Minn., can perform complex, yet minimally invasive surgery by directing robotic "hands" to assist in delicate surgery.

The surgeon's finger motions, conveyed through sophisticated joy sticks, direct the minute maneuvers carried out by two robotic hands holding surgical instruments.

The surgeon views the surgery on a computer screen, which shows an enlarged and three-dimensional view of the surgical area. The images are transmitted by a tiny camera with multiple lenses, which is attached to a third robotic hand.

"This technology enhances a surgeon's skills, making it easier to do more complex surgeries laparoscopically -- that is with incisions as small as one centimeter," says Michael Blute, M.D., a urologist at Mayo Clinic.

"Patients who have laparoscopic surgery, rather than open surgery, often recover more quickly and return to their normal activities sooner," says Dr. Blute.

Surgery for prostate removal
Mayo Clinic surgeons expect to use this new technology, called the da Vinci system, to remove prostate glands, a common treatment for prostate cancer, and for other urologic surgeries.

Prostate cancer is the second-leading cause of cancer deaths in American men. Surgery to remove the prostate gland, called radical prostatectomy, is one of the most effective ways to treat prostate cancer. Typically, radical prostatectomies are open surgeries, with larger incisions.

The da Vinci system was approved by the U.S. Food and Drug Administration in 2001 for prostate surgery. Last year, a handful of U.S. medical centers in the United States began using da Vinci for other types of general laparoscopic surgery and for some chest surgeries.

Laparoscopic surgery is not new, but a limited number of procedures can be done with this technique, and it requires years of surgical training.

"With the da Vinci, surgeons skilled in open surgery can use their expertise, and the help of robotic hands, to do more types of surgery laparoscopically," says Dr. Blute. "That has the potential to improve care for many of our patients."
-end-
Additional Contact Information:
507-284-2511 (evenings)

Mayo Clinic

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.